Expiration date: 11/2025
The composition and form of issue:
Powder for preparation of solution for the reception inside in sachets (sachet) and 1 Pak.
glucosamine sulfate 1.5 g
in box 20 PCs.
Tablets. 1 tablet contains:
glucosamine sulfate 750 mg
in the box 60 or 180 PCs.
Solution for injection for intramuscular injection 1 amp. 2 ml contains:
glucosamine sulfate 400 mg
in a contour acheikova packing 6 PCs. (complete with the solvent in vials of 1 ml) in cardboard pack 1 set.
Feature:
Glucosamine sulfate is a natural component of articular cartilage, physiologically present in the human body. Is an aminosaccharide with a low molecular weight, has been cleaned from macromolecular components.
Pharmacological action:
Fills deficit endogenous glucosamine sulfate. Glucosamine stimulates chondrocyte synthesis of proteoglycans (glycosaminoglycans and hyaluronic acid) synovial fluid inhibits the enzymes (collagenase, phospholipase A2, etc.) that cause destruction of cartilage prevents the formation of superoxide radicals, inhibits the activity of lysosomal enzymes initiates the process of fixation of sulfur in the synthesis chondroitinase acid and promotes normal deposition of calcium in bone tissue prevents the damaging action of corticosteroids on chondrocytes and impaired synthesis of glycosaminoglycans induced by NSAIDs.
Sulfonate groups also participate in the synthesis and metabolism of glycosaminoglycans of cartilage and solitaire side chains composed of proteoglycans, contributing to the retention of water in maintaining the elasticity of cartilage matrix.
Glucosamine sulfate stops the destruction of cartilage and reduce symptoms in osteoarthritis.
Pharmacokinetics:
Quickly and completely absorbed in the small intestine. After the/m introduction and ingestion easily overcome biological barriers and penetrates the tissues, mainly articular cartilage. T1/2 of 68 h
Description pharmacological action:
Clinical improvement usually occurs 2 weeks after the start of treatment, when the/m introduction — after 3-4 days and lasts for 8 weeks after drug withdrawal, allowing intermittent.
Indications:
Prevention and treatment of osteoarthritis of various localization (knee, hip, wrist joints, spine, etc.).
Contraindications:
Hypersensitivity, phenylketonuria (for powder, as it contains aspartame).
The solution for injection contains an auxiliary component lidocaine, so it is contraindicated in patients with severely impaired cardiac conduction and heart failure, and hypersensitivity to lidocaine.
Application of pregnancy and breast-feeding:
Data on the use of drugs in pregnancy and lactation are not available.
Side effects:
In rare cases, possible gastrointestinal disorders mild and transient in nature, allergic reactions (urticaria) rarely an injectable form may cause headache, visual disturbances (due to the presence of lidocaine).
Method of application and dose:
Powder: inside for 20 minutes before eating, the contents of 1 sachet dissolved in 200 ml of water and take 1 every day for 4-12 weeks. Courses may be repeated with an interval of 2 months.
Capsule: inside, during meal, and 1-2 caps. (depending on body weight and severity of the disease), 3 times a day.
Solution for injection: in/m pre-mix contents of the vial of the medication (vial A) with the solvent vial (vial B) in the same syringe and injected 3 ml of solution 3 times a week for 4-6 weeks.
To effectively combine the injection with the drug inside.
Precautions:
Solution for injection with caution in patients with severe chronic heart failure and hypotension.
Special instructions:
No data on the use of the drug in children under 12 years.
The product is compatible with NPVS and glucocorticoids.
